US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

389.60

+3.420.89%

Number of Gainers:5

Number of Losers:1

Number of Flat:- -

PE:- -

High:395.96

Open:386.50

Low:378.08

Close:386.19

Loading ...

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

bluebird bio Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts

BofA moves to No Rating on Bluebird Bio after deal announcement

Top Midday Decliners

MT Newswires Live

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Bluebird bio's CVR Payout Seen as a Stretch -- Market Talk

Bluebird Bio trading resumes

Bluebird Bio trading halted, volatility trading pause

Bluebird Bio downgraded to Neutral from Outperform at Baird

BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4556/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":389.60336,"timestamp":1741208399999,"preClose":386.18573,"halted":0,"volume":19681301,"delay":0,"changeRate":0.00885,"change":3.417633,"pbRate":1.915029,"amount":138049805.511814,"amplitude":0.046291,"prevYearClose":376.62552,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"turnoverRate":0.03606,"marketCap":7238271108,"floatMarketCap":6793444364,"peRate":-3.775699},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":395.95972,"amplitude":0.046291,"preClose":386.18573,"low":378.08292,"pbRate":"1.915029","latestPrice":389.60336,"volume":19681301,"delay":0,"open":386.49673,"prevYearClose":376.62552,"prevWeekClose":396.1103,"prevMonthClose":396.1103,"prevQuarterClose":376.6255,"fiveDayClose":408.0821,"twentyDayClose":376.4462,"sixtyDayClose":408.5231,"secType":"PLATE","market":"US","turnoverRate":0.03606,"peRate":-3.775699,"marketCap":7238271108,"floatMarketCap":6793444364,"timestamp":1741208399999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514093342","title":"Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093342","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093342?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031842/0/en/Beam-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Reiterates-Anticipated-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LENZ","BK4535","BK4588","ASH","LU2463526074.USD","BK4109","BK4556","SCD","BK4505","BEAM","BK4139"],"gpt_icon":0},{"id":"2513722401","title":"Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722401","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722401?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:15","pubTimestamp":1740406500,"startTime":"0","endTime":"0","summary":"Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform. Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability. SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc.  has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/illumina-transforms-multiomic-research-technologies-141500613.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illumina-transforms-multiomic-research-technologies-141500613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CRSP","LU1861559042.SGD","LU1861558580.USD","BK4588","BK4548","BK4585","ILMN","BK4556","BK4534","BK4121","BK4535"],"gpt_icon":0},{"id":"2513721098","title":"Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721098","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721098?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 24, 2025  -- Editas Medicine, Inc. , a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March:. TD Cowen 45th Annual Health Care Conference Format: Fireside ChatDate: Monday, March 3Time: 2:30 p.m. ETLocation: Boston, MA. Leerink Partners Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, March 10Time: 9:20 a.m. ETLocation: Miami, FL. Barclays 27th Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, March 11Time: 9:00 a.m. ETLocation: Miami, FL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/editas-medicine-announce-fourth-quarter-140000831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","BK4585","BK4139","LU1861559042.SGD","LU1861558580.USD","EDIT","BK4588","CRSP"],"gpt_icon":0},{"id":"2513720437","title":"2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720437","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513720437?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics and Intellia Therapeutics are both unprofitable gene-editing companies.Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next year.Take CRISPR Therapeutics  and Intellia Therapeutics , two biotechs specializing in gene editing. The former's average price target, according to Yahoo!Finance, is $83.60; the latter earns a price target of $50.80 from analysts. That implies an upside of about 66% for CRISPR Therapeutics and 415% for Intellia Therapeutics.These two companies have significantly lagged the market over the past three years. Could they turn around and live up to Wall Street's expectations?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/24/2-beaten-down-stocks-to-buy-before-they-soar-by-66/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4556","BK4585","BK4139","LU1861559042.SGD","LU1861558580.USD","BK4588","CRSP","SCD"],"gpt_icon":1},{"id":"2513280397","title":"Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513280397","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513280397?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 24, 2025  -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:. TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ET. About Beam TherapeuticsBeam Therapeutics  is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-participate-upcoming-march-120000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BEAM","LENZ","BK4556","BK4535","BK4585","BK4588","BK4139","BK4505"],"gpt_icon":0},{"id":"2513792033","title":"bluebird bio Inc : JP Morgan Raises to Neutral From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792033?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:23","pubTimestamp":1740374629,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2513800750","title":"Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513800750","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513800750?lang=en_us&edition=fundamental","pubTime":"2025-02-24 04:05","pubTimestamp":1740341119,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Beam Therapeutics Inc.  stands against the other best performing pharma stocks so far in 2025.On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump administration. Talking about the pharma’s agenda in Washington, where the big names of the pharma industry were set to meet with President Trump on February 20, Holz said that while it is tough to talk about the valuation of pharma companies, the significance of the meeting is to have a sort of collaborative effort between the industry and the government to see where they can move things over time. The stocks have exhibited either a little bit or a lot of worry over the RFK front, the United States Secretary of Health and Human Services. This was based on the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-beam-therapeutics-inc-beam-200519020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","NVIW.SI","BK4585","PSQ","BK4588","BK4139","BK4556","QID",".IXIC","TSYW.SI","NQmain","MNQmain","QLD","BK4505","BEAM","USJW.SI","TQQQ","SQQQ","USAW.SI"],"gpt_icon":1},{"id":"2513754757","title":"CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513754757","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513754757?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:34","pubTimestamp":1740335664,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CRISPR Therapeutics AG  stands against the other oversold pharma stocks to buy according to analysts.On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs. She believed the industry may not underperform this year, at least in the first half. However, there are still several questions surrounding the performance of obesity drugs, as major players in the domain have exhibited contrasting previous year performance.Angelica Peebles, CNBC’s Health and Pharma reporter, sat with Eli Lilly’s Chief Scientific Officer to talk about the weight loss sector. From the conversation, she reported that the domain poses opportunity for drugs that are easier to use, such as pills, and medicines that make peop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-most-183424796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","TQQQ","NVIW.SI","USAW.SI","BK4139","BK4210","MNQmain","QLD","NQmain","AG","BK4585","PSQ","TSYW.SI","LU1861559042.SGD","BK4556","LU1861558580.USD","SCD","SQQQ","BK4588","QID","CRSP",".IXIC"],"gpt_icon":1},{"id":"2513119162","title":"BofA moves to No Rating on Bluebird Bio after deal announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2513119162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513119162?lang=en_us&edition=fundamental","pubTime":"2025-02-22 03:20","pubTimestamp":1740165610,"startTime":"0","endTime":"0","summary":"BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and SK ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bofa-moves-to-no-rating-on-bluebird-bio-after-deal-announcement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bofa-moves-to-no-rating-on-bluebird-bio-after-deal-announcement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLUE","BK4578","BK4556"],"gpt_icon":0},{"id":"2513221677","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2513221677","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513221677?lang=en_us&edition=fundamental","pubTime":"2025-02-22 02:50","pubTimestamp":1740163822,"startTime":"0","endTime":"0","summary":"Bluebird Bio  said Friday it agreed to be acquired by Carlyle Group  managed funds and SK Capital Partners.Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027.Shares slumped 41% following a surge in intraday trading volume to over 4.5 million from a daily average of about 392,000.AXT  reported a wider Q4 non-GAAP loss late Thursday compared with a year ago and sequentially. Wedbush adjusted AXT's price target to $4.50 from $5.50 while maintaining its outperform rating.Shares of AXT sank 31%, with intraday trading volume catapulting to over 5.3 million versus a daily average of about 361,000.Akamai Technologies  has \"limited\" short-term growth opportunities, BofA Securities said in a note Friday, following the company's Q4 results overnight. BofA downgraded ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE00B64PRP62.GBP","BK4135","AXTI","BK4147","BK4578","BLUE","CG","IE00B3QW5Z07.USD","BK4585","LU2286300806.USD","IE00BGHQF748.EUR","BK4608","AKAM","BK4556","BK4139","BK4116","BK4554"],"gpt_icon":0},{"id":"2513213797","title":"Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes","url":"https://stock-news.laohu8.com/highlight/detail?id=2513213797","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513213797?lang=en_us&edition=fundamental","pubTime":"2025-02-22 01:35","pubTimestamp":1740159346,"startTime":"0","endTime":"0","summary":"According to multiple media reports on Thursday, PfizerInc.  has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.Also Read: uniQure/ CSL Behring’s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years. In a statement toNikkei Asia, Pfizer said the decision was due to \"the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.”The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.In December 2024, Pfizer walked awayfrom its hemophilia A co-development pact with Sangamo Therapeutics Inc  giroctocogene fitelparvovec, an investigational gene therapy product candidate.According to a Reuters report, Pfizer will continue to invest resources in Hympavzi , which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.Hympavzi is the first and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-discontinues-hemophilia-gene-therapy-173546804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0868494617.USD","IE00BZ1G4Q59.USD","LU1066051498.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4532","LU0234572021.USD","LU1883839398.USD","BK4550","SGMO","BK4534","LU0456855351.SGD","BK4533","SG9999011175.SGD","BK4588","SG9999001176.SGD","LU0306807586.USD","LU1066053197.SGD","LU1057294990.SGD","LU1093756168.USD","LU0321505868.SGD","SG9999013999.USD","IE00BBT3K403.USD","LU0321505439.SGD","SG9999002224.SGD","LU1023059063.AUD","PFE","BK4585","LU0170899867.USD","LU0225284248.USD","IE000M9KFDE8.USD","LU0058720904.USD","IE00BLSP4452.SGD","LU0985481810.HKD","SG9999001176.USD","BK4007","IE00BKVL7J92.USD","BK4592","IE0002270589.USD","LU0122379950.USD","SG9999003800.SGD","NVO","BK4568","LU0154236417.USD","LU0225771236.USD","LU1894683348.USD","BK4556","BK4581","SCD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2513321824","title":"Bluebird bio's CVR Payout Seen as a Stretch -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2513321824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513321824?lang=en_us&edition=fundamental","pubTime":"2025-02-22 01:24","pubTimestamp":1740158640,"startTime":"0","endTime":"0","summary":"1224 ET - Bluebird bio's deal to be taken private will leave investors with a rich reward or a steep haircut, depending on sales of the company's gene therapies over the next three years. Analysts at William Blair think it will be the latter. Bluebird holders will get an initial $3 a share, 57% below Thursday's closing price, but contingent value rights that would be triggered by 12-month sales of $600 million would bring another $6.84 a share, for a 40% premium. William Blair says it currently models bluebird's sales reaching only $546.4 million in 2027, making the probability of achieving the CVR contingency low. Bluebird slide 39% to $4.29. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BLUE","BK4139","BK4556","CVR","BK4578"],"gpt_icon":0},{"id":"2513299576","title":"Bluebird Bio trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513299576?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:40","pubTimestamp":1740148857,"startTime":"0","endTime":"0","summary":"09:37 EST Bluebird Bio (BLUE) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2513037295","title":"Bluebird Bio trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2513037295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513037295?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:36","pubTimestamp":1740148563,"startTime":"0","endTime":"0","summary":"09:32 EST Bluebird Bio (BLUE) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLUE","BK4556","BK4139","BK4578"],"gpt_icon":0},{"id":"2513029577","title":"Bluebird Bio downgraded to Neutral from Outperform at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2513029577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513029577?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:25","pubTimestamp":1740147918,"startTime":"0","endTime":"0","summary":"Baird analyst Jack Allen downgraded Bluebird Bio (BLUE) to Neutral from Outperform with a price target of $5, down from $54, after the company ente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-downgraded-to-neutral-from-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-downgraded-to-neutral-from-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4578","BK4556","BK4139","BLUE"],"gpt_icon":0},{"id":"2513931662","title":"BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513931662","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513931662?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:12","pubTimestamp":1740147171,"startTime":"0","endTime":"0","summary":"BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK CapitalFeb 21 (Reuters) - bluebird bio Inc BLUE.O:BLUEBIRD BIO ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY CARLY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nTUA8F6XRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BLUE","CG","BK4135","BK4139","BK4556","BK4578","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":60}]}}